Kantaro said that authorized clinical testing laboratories in Europe can use its enzyme-linked immunoassays, which detect IgG antibodies to two coronavirus antigens.
Mount Sinai researchers investigated four cytokine proteins and found that two of them were elevated in the serum samples of SARS-CoV-2 patients who fared the worst.
The London-based firm hopes to also show the clinical utility of its KidneyIntelX assay for predicting the risk of the patients' progressive kidney decline.
BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.
KidneyIntelX can be used to report risk assessment results for fast-progressing kidney disease and future kidney failure for patients with chronic kidney disease.
Kantaro and Bio-Techne have partnered to develop, manufacture, and distribute a kit based on a Mount Sinai assay that has received an Emergency Use Authorization.
